Idenix (NASDAQ:IDIX) -6% to $9.52 after launching a $150M offering of common stock, a day after saying that it's revising its partnership agreement with Novartis (NYSE:NVS). This includes Idenix no longer receiving royalty or milestone payments from the Swiss firm for hepatitis B drug Tyzeka. (PR)